Literature DB >> 20425249

Evidence for aggressive blood pressure-lowering goals in patients with coronary artery disease.

Monisankar Roy1, Noman Mahmood, Clive Rosendorff.   

Abstract

Lowering blood pressure (BP) reduces the risk of major cardiovascular mortality and morbidity. Current consensus targets for BP reduction are less than 140/90 mm Hg in uncomplicated hypertension and less than 130/80 mm Hg in those patients with diabetes, chronic kidney disease, and coronary artery disease or in those who are at high risk for developing coronary artery disease (defined as a Framingham risk score of > or = 10%). There is solid epidemiologic evidence for lower BP targets, supported by some clinical studies with surrogate end points. On the other hand, there are meager data from clinical trials using hard end points, and there is a concern that overly aggressive BP lowering, especially of diastolic BP, may impair coronary perfusion, particularly in patients with left ventricular hypertrophy and/or coronary artery disease. This review evaluates the evidence for the benefit of lower BP targets in hypertension management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425249     DOI: 10.1007/s11883-010-0094-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  39 in total

1.  Diastolic blood pressure and mortality in the elderly with cardiovascular disease.

Authors:  Athanase D Protogerou; Michel E Safar; Pierre Iaria; Hélène Safar; Katia Le Dudal; Jan Filipovsky; Olivier Henry; Pierre Ducimetière; Jacques Blacher
Journal:  Hypertension       Date:  2007-05-21       Impact factor: 10.190

2.  Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function.

Authors:  Dogan Erdogan; Ibrahim Yildirim; Ozgur Ciftci; Ismail Ozer; Mustafa Caliskan; Hakan Gullu; Haldun Muderrisoglu
Journal:  Circulation       Date:  2007-02-06       Impact factor: 29.690

3.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

Authors:  L Liu; J G Wang; L Gong; G Liu; J A Staessen
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

4.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

Review 6.  Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure.

Authors:  Joseph L Izzo; Alan H Gradman
Journal:  Med Clin North Am       Date:  2004-09       Impact factor: 5.456

7.  Angiotensin inhibition and coronary autoregulation in a canine model of LV hypertrophy.

Authors:  Jacques R Rouleau; Denis Simard; André Blouin; John G Kingma
Journal:  Basic Res Cardiol       Date:  2002-09       Impact factor: 17.165

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

9.  Low diastolic blood pressure and mortality in a population-based cohort of 16913 hypertensive patients in North Karelia, Finland.

Authors:  J Tuomilehto; O P Ryynänen; A Koistinen; D Rastenyte; A Nissinen; P Puska
Journal:  J Hypertens       Date:  1998-09       Impact factor: 4.844

10.  Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial.

Authors:  Paolo Verdecchia; Jan A Staessen; Fabio Angeli; Giovanni de Simone; Augusto Achilli; Antonello Ganau; Gianfrancesco Mureddu; Sergio Pede; Aldo P Maggioni; Donata Lucci; Gianpaolo Reboldi
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

View more
  4 in total

Review 1.  Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.

Authors:  George L Bakris
Journal:  Mayo Clin Proc       Date:  2011-05       Impact factor: 7.616

Review 2.  Establishing targets for hypertension control in patients with comorbidities.

Authors:  Carlos Feldstein; Stevo Julius
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

Review 3.  Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.

Authors:  Luis Carlos Saiz; Javier Gorricho; Javier Garjón; Mª Concepción Celaya; Juan Erviti; Leire Leache
Journal:  Cochrane Database Syst Rev       Date:  2018-07-20

4.  Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.

Authors:  Luis Carlos Saiz; Javier Gorricho; Javier Garjón; Mª Concepción Celaya; Juan Erviti; Leire Leache
Journal:  Cochrane Database Syst Rev       Date:  2020-09-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.